NIM
AGRX

Needham Investment Management’s Agile Therapeutics AGRX Stock Holding History

Needham Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-175
Closed -$171K – 131
2021
Q4 		$171K Sell
175
-193
-52% -$272K 0.02% 117
2021
Q3 		$706K Hold
368
– – 0.09% 100
2021
Q2 		$978K Hold
368
– – 0.14% 87
2021
Q1 		$1.53M Buy
368
+68
+23% +$368K 0.21% 78
2020
Q4 		$1.72M Buy
+300
New +$1.77M 0.29% 74
2019
Q4 		– Sell
-28
Closed -$65K – 103
2019
Q3 		$65K Sell
28
-20
-42% -$49.3K 0.02% 86
2019
Q2 		$139K Sell
48
-32
-40% -$89.4K 0.05% 83
2019
Q1 		$242K Buy
80
+40
+100% +$84.8K 0.08% 77
2018
Q4 		$46K Sell
40
-75
-65% -$115K 0.02% 83
2018
Q3 		$85K Sell
115
-8
-7% -$5.86K 0.03% 85
2018
Q2 		$121K Sell
123
-91
-43% -$319K 0.03% 90
2018
Q1 		$1.1M Buy
214
+10
+5% +$66.1K 0.31% 57
2017
Q4 		$1.1M Sell
204
-48
-19% -$447K 0.29% 60
2017
Q3 		$2.25M Buy
252
+37
+17% +$284K 0.57% 50
2017
Q2 		$1.61M Buy
215
+102
+90% +$706K 0.43% 52
2017
Q1 		$725K Buy
113
+43
+61% +$216K 0.19% 72
2016
Q4 		$799K Buy
70
+47
+204% +$659K 0.2% 73
2016
Q3 		$314K Buy
+23
New +$328K 0.08% 82

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Needham Investment Management's AGRX Position: Q1 2022 in Review

Needham Investment Management sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 175 shares — an estimated $171K sold.

Needham Investment Management first reported a position in AGRX in Q3 2016 and held it in 18 quarters. The position peaked at $2.25M in Q3 2017. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • Needham Investment Management reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Needham Investment Management sold 175 Agile Therapeutics shares in Q1 2022, an estimated $171K.
  • Needham Investment Management first reported a position in Agile Therapeutics in Q3 2016 and held it in 18 quarters.
  • Needham Investment Management's Agile Therapeutics position peaked at $2.25M in Q3 2017.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on Needham Investment Management's 13F filing for Q1 2022, filed 16 May 2022.